Lundbeck Baffled After German Assessment Snub, Novo Also Hit Again
This article was originally published in Scrip
Executive Summary
Germany's health technology assessment body the Institute for Quality and Efficiency in Healthcare (IQWiG) has concluded Novo Nordisk's new antidiabetic Xultophy (insulin degludec plus liraglutide) and H. Lundbeck's antidepressant Brintellix (vortioxetine) bring no additional benefits to clinical practice, raising concerns yet again about how it evaluates new medicines.